Technical Data Sheets MSDS OF CALCIUM OROTATE
|Appearance||White to off – white powder|
|Solubility||Hardly Soluble in water|
|Shall Pass the test
shall pass the test
|Specific absorbance by UV
|A 1 cm (1.0%) 280 – 320|
|Amino acid test on 1gm
|shall be absent|
|Alkalinity test on 1.5gm of
substance suspended in
30ml of water, stir for 5 min
|10ml of filtrate solution
should not consume more
than 0.5ml of 0.01N NaoH
|Total heavy metals||Not more than 20ppm|
|Sulphate||Not more than 20ppm|
|Assay by EDTA titration||Between 98% – 102%|
Calcium Orotate is better than other sources of calcium to treat calcium deficiency. Orotic acid moiety,since it is produced naturally in human body,is recognized by the transporter enzyme of the cell to transport across cell wall to make it available to the cell. While calcium is used up in the body to build bones and teeth, orotic acid goes on to produce nucleic acids. Calcium Orotate has other applications besides the well know treatment of osteoporosis. For the benefit of people who wish to know more about calcium orotate we are attaching herewith a treatise on the subject done by Dr.H.A.Nieper,M.D. of Hannover Calcium Orotate is used for
- Inflammatory conditions, such as psoriasis, lupus, arthritis, spondylitis, encephalitis, retinitis, phlebitis, colitis;
- viral infections, such as hepatitis;
- cardiovascular conditions, such as angina and hypertension;
- neurological problems, such as chronic overeating and glum moods
Molecular Formula : C10 H 6 Ca N 4 O 8
Molecular Weight : 350
CAS No. : 22454-86-0
EC No. : 245-009-2
Appearance : White to off-white crystals or powder.
Solubility : Soluble in dilute hydrochloric acid
Assay (EDTA Titration) : 98.00 101.00 %
Material should be re-tested against certificate of analysis three years from date of manufacture. Store in an air tight container at 25-30 ℃
Calcium orotate is absolutely free of any side effects and in this respect, it is far superior to all the conventional calcium salts now being used. Because calcium orotate can penetrate the complex cell membranes, it can compensate for a disturbed calcium transport through these cell membranes. In addition, calcium orotate has a special affinity for bradytrophic tissue– cartilage, for example–where it is metabolized.
Previous experience up to now: Calcium orotate has been used extensively since 1968, to treat decalcification conditions and even in many cases, immunological diseases. The results accomplished are in complete accord with what was discovered in 1959 concerning the transrnembrane transport complex. Calcium is first released as an ion, on the cytoplasma membrane level, because orotic acid is chiefly metabolized there, not in the outer cell membrane. The clinical results that seen up to now are very encouraging, with a minimum of side effects completely unparalleled with anything that in the entire field of calcium supplementation.
And what is more, in suitable cases, this substance is a very satisfactory agent in the recalcification of metastatic defects in the skeletal system . The results of calcium orotate therapy with juvenile decalcification and with osteoporosis of the aged, are completely satisfactory for the first time, especially in view of the absence of side effects.
The very remarkable results achieved in hip joint plastic surgery are due to a hardening of the bone by preliminary treatment with calcium orotate. Hopeless immobilization is replaced by fully normal, pain-free locomotive ability. This may be accomplished after about 2.5g calcium orotate2 for 10 weeks. A long period of therapy with a conventional calcium carbnate carried out has no effect.
Calcium orotate and Liver: A several year search through many long term treatments with calcium orotate for side effects was absolutely negative. On the contrary, a whole series of positive observations have come to light, which may be connected with the unique transmembrane calcium transport.
One noteworthy observation is that patients with chronic cholangitis and light cases of chronic hepatitis–and also in severe aggressive cases–show a considerable improvement in their ailments, their state of health, their gall function, and to some extent, their biochemical and biological findings. This is especially true under long term therapy. It appears to be associated with an anti-inflammatory effect on the mesenchymal stroma system in the liver. The carrier molecule–orotic acid–has an especially high affinity for mesenchymal tissue . Calcium orotate liberates its calcium ion–this is the classic anti-inflammatory principle- -at the level of the mitochondrial membrane. This explains the anti-inflammatory effect in the liver. In a test four patients who had taken, on the average, 3g of calcium orotate in stomach acid resistant capsules per day, for more than a year, submitted to a liver puncture. (For reasons which had nothing to do with the application of calcium orotate.) In all cases there was no sign of fatty liver development. Quite the contrary, three of the patients with stage 3 fatty liver were reportedto have shown a remarkable improvement under long term calcium orotate therapy
The lipase enzymes which are necessary for the mobilization of stored fat, are activated by Ca++.The primary source of fatty liver is a defective calcium transit in the liver cell. A magnesium washout caused by chronic alcoholism, in the liver cell membrane, could explain this. Mg++ is necessary in the cell membrane for Ca- transit into the cell. Anything which disturbs or injures the cell membrane function can affect calcium transit through the cell membrane. So there are possibly some other significant considerations, such as essential hypertonia or the ingestion of detergents which stick to kitchen utensils after washing. Also a fare too rich in carbohydrates puts a strain on the P-pools and likewise interrupts the Ca- transport through the membranes.
Effect on heart and circulation: Another interesting observation is of a moderate, to often marked, dropping of the blood pressure with fixed hypertonia. This treatment will elevate the lowered blood pressure both in the chronic, as well as the light form of renal hypertonia. Normal blood pressure is not affected. What is especially convincing is the disappearance of angina pains, especially with a hypertrophied heart. In addition, the improvement is remarkably good with infarct anamnesis with hypertonia and a distinct sclerosis of the heart. Digitalis or Strophanthin tolerance appears to be better. With a dosage of l0g calcium orotatetgl., no incompatibility of Digitalis can be observed, in the EKG, subjectively, or otherwise. Probably because no membraneous calcium ions are created. In this connection, I must point out that some time ago, KAUFMANN and coworkers (KAUFMANN and MITARBEIT) , researched the problem of defective or insufficient calcium transit in hypertrophia of the heart muscles. They conclude, that this is the reason for contractile insufficiency, in hypertrophy and other metabolic problems of the hypertrophic heart. Special reference must be made to the papers of the KAUFMANN group. We have made a series of tests with 14 year old dogs on a 14 percent incline. Our results were a very good confirmation of the pathogenetic mechanism that KAUFMANN portrayed. We will give you the details in a later article. RILLING has verified the research of ZONDEK and KYLIN with his comprehensive spectrographic studies. These authors maintain that essential hypertonia is a cellular calcium-deficient pathognomonic condition. This interpretation is much the same as KAUFMANN’S explanation of heart muscle hypertrophy and would explain the blood pressure lowering effect of calcium orotate. At the time that NlEPER and LABORIT were doing clinical research on potassium magnesium aspartate, we hoped to be able to correct disturbances of the heart action regulation system. Except for a suppression of ventricular and supraventricular extrastole, this hope was not realized. As you know, the heart action regulation system is musculature in nature, which consists of a different type of metabolism, the direct oxygen or ‘pentose pathway”. The stimulatory regulation and ganglion tissue provide especially good protection against oxygen deficiency intrafetally and later. Orotic acid plays an essential role in the pentose pathway, and so appears to be the electrolyte transporter needed for that tissue. In view of that, it should not be surprising to learn that we were able to normalize apparently therapy-resistant tachyarrhythmia with auricle flutter, in three cases, with a dosage of 5g calcium tgl. After this excursus, I would like to mention the immune-inhibiting effect (as already reported) of calcium orotate on a succession of bradytrophictssues.
Specific effect on cartilage: It was first reported by WHITE towards the end of 1969, that calcium orotate showed an astounding curative effect on the Tietze syndrome. These reports were repeated over and over during 1970 and 1971, so that we were induced to try calcium orotate in three cases of stubborn Tietze syndrome. The effect of the calcium orotate was indeed surprising.The syndrome is suppressed by very low doses–down to 1g/week, which we could verify. A dosage of 500mg/day is fully effective, it is highly significant that there is no effect whatsoever from calcium EAP, calcium-L dl aspartate (calciretard), calcium gluconate, calcium citrate, magnesium orotate, and K-Mgaspartate, upon the Tietze syndrome.
On the basis of our knowledge of the effect of calcium orotate on the Tietze syndrome, we must conclude, that a favorable trophic effect on the cartilaginous intervertebral substance is the reason for the not infrequently spectacular improvement of the patient.
This fully specific effect of calcium orotate on cartilage, as evidenced by the Tietze syndrome experience, appears now to be of tremendous . While treating patients with spinal column syndrome and calcification damage, it had been apparent, for a long time, that the reported and verified improvement of their condition, must be attributed to more than simply an influence on the bone tissue. In a trial with five patients (f) and one patient (m) from 26 to 76 years, with symptoms of weakness and painful sensitivity in the wrists. In three cases, it could be observed only with an sphygmomanometer, and in three cases observation was not possible at all. In every case, the complaints disappeared with calcium orotate therapy. Upon the removal of the therapy, or when the dosage was insufficient (less than about 1.6g/ week) the complaints returned. Especially puzzling were the findings for 18 patients from files, in which there were severe dislocating alterations of the spinal column. Treated with calcium orotate, these patients became exceptionally free of complaints. Other medications – Butazonderivate, cortisone, indomethacin, physical therapy, gold medication – had failed. Even intensive treatment with calcium EAP, and calciretard along with calcim-sandoz and K-Mg-aspartate were ineffectual.
In a case history:A patient (f) 64 years Severe complaint complex with LWS syndrome. Every imaginable therapeutic preventive measure taken to no avail. Infusion treatment with calcium-L-dl aspartate (calciretard) plus calcium EAP for more than six months. Complete stationary immobilization for three months 1970/71 to no avail. The pain associated with the LWS syndrome had forced her almost to the point of complete immobility. About three to five weeks after starting calcium orotate therapy–an average of 3g/daily—the patient was complaint free and remained so for 16 months–practically normal movement and walking ability. In contrast to calcium orotate, other calcium transporters such as calcium EAP and calciretard were fully ineffective. Is the improvement to be sought in a structurally favorable influence of the intervertebral tissue?
Almost complaint free after six weeks intensive treatment with calcium orotate. Reconstruction mainly in the gap between 3 and 4. LWK Both developments are stabilized. These findings are not the only ones which gave rise to questions about the effectiveness of calcium orotate on cartilage. In 1968 calcium orotatewas usedto treat patients with definite Bechterewschen disease. There were, in all, five such patients and in all the cases the very intense pain in the spinal column disappeared for the most part. All previous treatments–phenylbutazone, cortisone, gold therapy and healing baths–had been ineffective. Illustration 3.. patient (F) N. N. 56 years.
In 1963, the disease has progressed so far in this 56 year old patient, that she was almost completely immobilized. In spite of standard therapies and seltzer water cure, the progression continued. By 1968 the face was almost in a fixed position, movement and sitting were almost impossible. 1.5g calcium orotate was prescribed daily for 54 months continuously. No more complaints. The face could be moved normally and the patient resumed her household duties. The second is the patient (F) with MorbusBechterew after 54 months continuous treatment with calcium orotate. Patient (f) M.B. 71 years had most severe complaints for three years as a result of spondylitic arthrosis deformation. Treatment with phenylbutazone and also in combination with cortisone and with pyrazolone showed only slight palliative effect. Calcium-sandoz forte tgl. 3 tabl. for over four months without any effect. After 10 days tgl. 5g calcium orotate, the patient was almost complaint free, and has remained that way. patient (F) N.B. 81 years, A sister of Frau M.B. above. 10 years older. X-rays and symptom complex indicate a very severe case. After being treated with calcium orotatetgl. 3g. she became complaint free, that she again took up vigorous employment after previous inactivity. Patient R. 79 years (f) Frau R., mentally and bodily vigorous. Had an acute attack of a long time existing osteochondrosis. Quite comfortable lying down, but experienced immediate unbearable pain in the spinal column upon standing up. After treatment with 5g calcium orotate daily, the patient became complaint free within three weeks. The pain had previously worsened under cortisone therapy. Calcium-gluconate-citrate, phenylbutazone and indomethazine had no effect whatsoever. The curative effect of calcium orotate was permanent (now over 14 months).
Patient (in) St. 55 years acute monarthritis of the right tibiotarsal joint, forcing him almost to the point of immobilization. Three tablets realin daily were of very little effect. Soludecortin H 50mg likewise. Volon 80 brought limited relief for 36 hours. Calcium orotate 8 tabl. each .5g daily brought improvement after 2 days and corrected the condition in 6. There are four similar cases. By the end of 1972, we had experience with 21 cases of deforming spondylarthosis–five men, sixteen women, from 58 years up. Clinical and objective findings were consistent with the cases mentioned previously. 14 out of 16 women and 4 out of 5 men were helped by calcium orotate alone. They were observed for over a year. The remarkable effect of calcium orotate (called Ca orotate for short) with Tietze syndrome in the intervertebral disk (and possibly in the ligamentous apparatus) causes us to again evaluate the metabolic specificity of cartilage and other bradytrophic tissue. Here the pentose pathway (so-called direct oxidation) plays a very crucial role–an extremely old phylogenetic-metabolic pathway, which is not dependent upon the erythrocyte oxygen donation. In the pentose pathway, the ribose is activated through orotate coupling. For this reason, orotic acid plays a very essential role in the pentose pathway. Here we are concerned with a large variety of tissues. Besides cartilage and ligamentous tissue, there is the connective tissue, the skin, the walls of the blood vessels, a specific section of the venules in the blood-brain-barrier, the heart stimulation-regulation tissue and keratin building tissue (hair, nails, etc.). Also the pentose pathway plays a very important role in the bone matrix, in the heart muscle and in the liver (both in the liver cells and in the stroma). The aromatic structure of the orotic acid is responsible for the high complex stability of the salts, and the already mentioned highly complex passage though the cell membrane typical of orotic acid, plainly make the orotate an ideal mineral transporter.  We are indebted to the tireless effort of LABORIT  and his scholars  who made public the results of their year-long research program which disclosed the vital effect of the pentose pathway in the function and structure of bradytrophic tissue. Life would not be possible without It. Previously, cartilage and connective tissue had been considered uninfluencable, for the most part. If calcium orotate can bring about a change here, as was demonstrated, then there is not much value in the geriatric therapeutic concept.
Summary An orientation is given concerning the clinical effects of calcium orotate (called Ca orotate for short). Because calcium orotate is free from side effects, It is superior to conventional calcium salts, which have certain problems when applied in osteoporosis with concomitant arteriosclerosis of the abdominal aorta. Calcium orotate, an the other hand, protects the body from arteriosclerosis. Calcium, for this reason, is of value as a food supplement when used in the form of calcium orotate, which can penetrate the cell membranes as a complex form, compensating for defective calcium transit into the cells. In addition, calcium orotate has a special affinity for cartilage and other bradtrophic tissue, where it is metabolized. Not only is the basic principle of action quite simple, but the long time therapeutic effects are of considerable interest. A new dimension of therapy now appears with the improvements in osteochondrosis and disk degeneration treatment. Far better than the present therapeutic possibilities. Much the same observations seem to apply to osteoporosis. Parallel investigations point to the important pathogenetic significance of a defective calcium transport through the cell membrane. This is the case, for example, in hypertensions–especially essential hypertension–in fatty liver, in disturbances of the ductile of the heart, and in contractile and metabolic insufficiency of the hypertrophic myocardium. In respect to all of these indications, calcium seems to bring about the most promising therapeutic results, when combined with the carrier orotic acid for better transmembrane transport, in the form of calcium orotate.